Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Drug Combination Details

General Information of the Combination (ID: C35498)
Name Salicylic acid   NP Info  + 5-fluorouracil   Drug Info 
Structure +
Disease
Actinic keratoses on the hands and/or forearms [ICD-11: EK90]
Phase 3 [1]
Common warts [ICD-11: 1E80]
Investigative [2]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Enhancing Drug Efficacy by This Combination
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [2]
                    In-vivo Model Medical record review
                    Experimental
                    Result(s)
It was observed that the twice-daily application of topical fluorouracil and salicylic acid is a safe and effective treatment for verruca plantaris.
References
Reference 1 ClinicalTrials.gov (NCT02289768) Study To Evaluate The Efficacy And Safety Of Actikerall Solution In Patients With Grade I-II Actinic Keratoses.
Reference 2 Treatment of verruca plantaris with a combination of topical fluorouracil and salicylic acid. J Am Podiatr Med Assoc. Jul-Aug 2005;95(4):366-9.
Reference 3 Low-dose 5-fluorouracil in combination with salicylic acid for the treatment of actinic keratoses on the hands and/or forearms - results of a non-interventional study. J Eur Acad Dermatol Venereol. 2017 Mar;31(3):455-462.
Reference 4 Combination therapy with 5-fluorouracil and salicylic acid in a treatment-resistant case of filiform facial warts. Dermatol Ther. 2020 Mar;33(2):e13235.
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China